Synthetic tripeptide bioregulator

Pinealon

aka EDR · Glu-Asp-Arg

Evidence grade
Grade C: Preliminary human data
for cognition, sleep and neuroprotection
User score everyone · n = 10
US FDA Not approved checked 2026-11-13
WADA 2026 Likely prohibited (S0) by class rule · checked 2026-11-13
EU No EMA approval found; national authorization status was not individually verified. · checked 2026-11-13

Grade note: Human data only from multi-ingredient mixtures.

Goals: Sleep · Cognition & mood Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

0 men aged 45–60

No reports in this group yet.

All men

1 man

small sample · n = 1

Outcome no effect 1 of 1

Side effects none reported

Stopped 0 of 1 Used with other compounds 0 of 1

Everyone

10 people

  • Positive: 4 of 10 (40%)
  • Mixed: 1 of 10 (10%)
  • Negative: 4 of 10 (40%)
  • No effect: 1 of 10 (10%)
  • Unclear: 1 of 10 (10%)
Benefits reported of 10
Benefits reported (n = 10)
ItemReports
Sleep5 of 10 (50%)
Focus / cognition3 of 10 (30%)
Mood / anxiety2 of 10 (20%)
Endurance1 of 10 (10%)
Energy1 of 10 (10%)
Recovery1 of 10 (10%)
Strength1 of 10 (10%)
Side effects reported of 10
Side effects reported (n = 10)
ItemReports
Insomnia2 of 10 (20%)
Vivid dreams2 of 10 (20%)
Anxiety1 of 10 (10%)
Fatigue1 of 10 (10%)
Low mood1 of 10 (10%)
Other1 of 10 (10%)
Why people stopped of 10
Why people stopped (n = 10)
ItemReports
Side effects1 of 10 (10%)

Stopped 1 of 10 (10%) Used with other compounds 5 of 10 (50%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “For me personally, Pinealon had no meaningful impact on sleep or recovery.”

  • “The data backs up my anecdotal experience of significantly better sleep.”

  • “Within 30 minutes I was feeling extremely irritated.”

  • “NOW, I'm waking up to four hours early every day.”

  • “I started Epitalon (0.5mg ED) & Pinealon (1mg ED) two weeks ago to improve sleep metrics. I have tracked sleep on my Garmin”

  • “Morning Fog Removal: I still need standard willpower to get out of bed, but the painful, heavy cloud in my head is practically gone.”

  • “I've noticed a bit more clear headedness and level headedness, less goofy, but not in a blunted way”

Read summaries and method notes

Read 1. No verified male self-reporter in the 45–60 bracket was found; the one clearly male author described himself only as being in his early-to-mid 40s and reported no meaningful sleep improvement. Across eight coded users, positive claims involved sleep quality, cognitive clarity, and physical performance, while negative reports involved disrupted sleep, irritation, vivid dreams, and substantial next-day fatigue. One two-week sleep improvement report combined Pinealon with Epitalon, and a cognitive improvement report combined it with Semax. Another user described persistent sleep disruption after taking Pinealon and Epitalon together. The sample does not distinguish the effect of Pinealon from co-administered compounds or ordinary variation in sleep, and reported durations ranged from days to approximately one month.

Read 2. No man aged 45–60; one man (early-to-mid 40s) noticed nothing after four evening injections. Seven users: 3 positive, 2 negative, 1 no effect, 1 unclear. Positives came with Epitalon (better Garmin sleep/recovery over 2 weeks) or Semax (morning brain fog gone, calmer ADHD regulation). One user had acute rage within 30 minutes of 2 mg before bed with vivid, unrefreshing dreams; another reacted badly after two weeks with Epitalon.

Note 1. A male describing himself as early/mid 40s was not assumed to be 45 or older. A research-subject account describing a third person was excluded. One author posting under another account in a follow-up was deduplicated after explicitly identifying themselves as the original poster. Some reported adverse effects were subsequently attributed by users to interactions with GLP-1 medication. The intranasal report also involved multiple supplements.

Note 2. The early/mid-40s man falls below 45 and is in all men only. Three of seven stacked with Epitalon or Semax.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Synthetic tripeptide bioregulator.

Proposed mechanism

Synthetic tripeptide Glu-Asp-Arg (EDR), ~418 Da, from the Khavinson "short peptide bioregulator" family — sibling of Epitalon (AEDG). The proposed mechanism is epigenetic: small enough to cross into cells and nuclei, bind chromatin/promoter regions in cortical and pineal tissue, and shift expression of antioxidant (SOD, GPx) and anti-apoptotic genes. Nuclear entry and chromatin interactions have laboratory support but do not demonstrate human brain penetration, pineal restoration or therapeutic gene regulation. Marketed as a pineal-directed geroprotector.

Route: intranasal, SubQ or oral. The original page recorded a Reddit consensus that intranasal is felt most, with one user reporting SubQ as markedly weaker. The protocol corpus gathered 2026-08-18 runs the other way — SubQ dominates the reported regimes, and intranasal appears mainly as a ~1-week bridge before switching to SubQ, with users describing the spray as mildly caustic. Both readings are left standing; neither is more than aggregated anecdote.

Safety

  • Human safety, pharmacokinetics and injection risks are not adequately characterized
  • A small report involving Pinealon and Vesugen observed pro-oxidant markers and lower circulating CD34-positive cells; causality and clinical meaning are uncertain

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence C cognition, sleep and neuroprotection

C stands, at the very bottom of C. Pinealon has been given to humans in two published reports, but always alongside or interchangeably with other peptides, with unclear allocation, so its own effect cannot be isolated. Held at C because the rubric's D is for 'animal / in-vitro only' and SNAP-8 (also only multi-ingredient human studies) is graded the same way. If the handbook requires compound-isolating human evidence for C, both pinealon and SNAP-8 drop to D.

Human trials · 2

  1. PMID 263906122015Small clinical report; allocation and blinding unclear 32 people

    Adults aged 41–83 with multiple chronic illnesses and organic brain syndrome in remission

    Reports biological-age markers and pro-oxidant activity with Pinealon and/or Vesugen; the individual peptide's effects cannot be isolated from the abstract. Source

  2. PMID 237345212012Occupational comparison with poorly described peptide intervention 300 people

    150 male truck drivers and 150 metalworkers screened; treatment-arm numbers not stated

    The authors report improved psychological measures with peptide combinations, but the comparison workers are not an established placebo group and Pinealon's contribution is uncertain. Source

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

No data.

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety 3 out of 5
  • Sleep 4 out of 5
  • Recovery not rated —
  • Cognitive not rated —

Sources

  1. pubmed.ncbi.nlm.nih.gov/26390612/
  2. pubmed.ncbi.nlm.nih.gov/23734521/
  3. hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  4. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf?embed=
  5. pmc.ncbi.nlm.nih.gov/articles/PMC7795577/
  6. pubmed.ncbi.nlm.nih.gov/34071923/
  7. pubmed.ncbi.nlm.nih.gov/39861198/
  8. pubmed.ncbi.nlm.nih.gov/40908429/
  9. clinicaltrials.gov/search?intr=Pinealon
  10. fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-5

Reddit threads read · 11

4 further sources on commercial or non-primary hosts not listed.

Research checked 2026-11-13.